Biotech stocks with the lowest PE ratio
Share price divided by earnings per share over the last twelve months. As of .
- Ranked
- 16
- of 146 biotech stocks we cover
- Median
- 25.4×
- Lowest
- 11.1×
- PLX
- Range
- 11.1× to 237×
median 25.4×
11.1×237×
| # | Company | PE | PE vs its 10 years | Revenue growth (TTM) | Market cap |
|---|---|---|---|---|---|
| 1 | PLXProtalix BioTherapeutics | 11.1× | 8th pct | +30.1% | $206.3M |
| 2 | MGTXMeiraGTx | 13.1× | n/a | n/m | $895.1M |
| 3 | INCYIncyte | 15.3× | 5th pct | +26.9% | $24.3B |
| 4 | ADMAAdma Biologics | 15.8× | 23rd pct | +8.0% | $2.5B |
| 5 | NBIXNeurocrine Biosciences | 21.3× | 6th pct | +34.4% | $14.8B |
| 6 | UTHRUnited Therapeutics | 21.6× | 99th pct | +2.5% | $25.9B |
| 7 | EXELExelixis | 22.1× | 48th pct | +9.2% | $17.4B |
| 8 | REGNRegeneron Pharmaceuticals | 24.0× | 65th pct | +9.3% | $100B |
| 9 | ALNYAlnylam Pharmaceuticals | 26.7× | n/a | +95.1% | $21.2B |
| 10 | VRTXVertex Pharmaceuticals | 31.5× | 69th pct | +10.5% | $137.1B |
| 11 | KRYSKrystal Biotech | 37.1× | 25th pct | +22.6% | $8.8B |
| 12 | HALOHalozyme Therapeutics | 38.5× | 89th pct | +41.2% | $14.6B |
| 13 | TECHBIO-TECHNE | 63.2× | 54th pct | −0.4% | $11.4B |
| 14 | ONCBeOne Medicines | 63.2× | n/a | +34.3% | $40.2B |
| 15 | VCELVericel | 88.1× | 13th pct | +23.0% | $2.1B |
| 16 | RGENRepligen | 237× | 86th pct | +16.5% | $9.8B |
Not ranked: 103 with a loss over the last year, 6 with not a meaningful number, 2 with a quarter missing. 19 companies whose data behind this number has a caveat are left out until it is checked.
A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.